| Year |
Citation |
Score |
| 2024 |
Nielsen W, Strand V, Simon LS, Parodis I, Kim AHJ, Desai M, Enman Y, Wallace D, Chaichian Y, Navarra S, Aranow C, MacKay M, Trotter K, Tayer-Shifman OE, Duarte-Garcia A, ... ... Touma Z, et al. OMERACT 2023 Systemic Lupus Erythematosus Special Interest Group: Winnowing and Binning Preliminary Candidate Domains for the Core Outcome Set. Seminars in Arthritis and Rheumatism. 65: 152380. PMID 38281467 DOI: 10.1016/j.semarthrit.2024.152380 |
0.495 |
|
| 2024 |
Whittall-Garcia LP, Naderinabi F, Gladman DD, Urowitz M, Touma Z, Konvalinka A, Wither J. Circulating neutrophil extracellular trap remnants as a biomarker to predict outcomes in lupus nephritis. Lupus Science & Medicine. 11. PMID 38177067 DOI: 10.1136/lupus-2023-001038 |
0.401 |
|
| 2023 |
Manion K, Muñoz-Grajales C, Kim M, Atenafu E, Faheem Z, Gladman DD, Urowitz M, Touma Z, Wither JE. Different Immunologic Profiles are Associated with Distinct Clinical Phenotypes in Longitudinally Followed Systemic Lupus Erythematosus Patients. Arthritis & Rheumatology (Hoboken, N.J.). PMID 38073017 DOI: 10.1002/art.42776 |
0.54 |
|
| 2023 |
Muñoz-Grajales C, Yilmaz EB, Svenungsson E, Touma Z. Systemic lupus erythematosus and damage: What has changed over the past 20 years? Best Practice & Research. Clinical Rheumatology. 101893. PMID 37993371 DOI: 10.1016/j.berh.2023.101893 |
0.337 |
|
| 2023 |
Whittall-Garcia L, Gladman DD, Urowitz MB, Touma Z, Johnson SR. Correspondence on "relationship between the EULAR/ACR classification criteria and organ damage in systemic lupus erythematosus" by Chi Chiu Mok et al. Lupus. 32: 810-811. PMID 37125665 DOI: 10.1177/09612033231171365 |
0.416 |
|
| 2023 |
Tang TS, Liao F, Webber D, Gold N, Cao J, Dominguez D, Gladman D, Knight A, Levy DM, Ng L, Paterson AD, Touma Z, Urowitz MB, Wither J, Silverman ED, et al. Genetics of longitudinal kidney function in children and adults with systemic lupus erythematosus. Rheumatology (Oxford, England). PMID 36916720 DOI: 10.1093/rheumatology/kead119 |
0.454 |
|
| 2023 |
Webber D, Cao J, Dominguez D, Gladman DD, Knight A, Levy DM, Liao F, Ng L, Paterson AD, Touma Z, Wither J, Urowitz M, Silverman ED, Hiraki LT. Genetics of Osteonecrosis in Children and Adults with Systemic Lupus Erythematosus. Rheumatology (Oxford, England). PMID 36651668 DOI: 10.1093/rheumatology/kead016 |
0.418 |
|
| 2022 |
Banjari M, Touma Z, Gladman DD. Improving measures of disease activity in systemic lupus erythematosus. Expert Review of Clinical Immunology. 1-10. PMID 36503376 DOI: 10.1080/1744666X.2023.2156339 |
0.352 |
|
| 2022 |
Johnson SR, Martinez JPD, Whittall-Garcia L, Urowitz MB, Gladman DD, Touma Z. Evaluating the threshold score for classification of systemic lupus erythematosus using the EULAR/ACR criteria. The Journal of Rheumatology. PMID 36319012 DOI: 10.3899/jrheum.220100 |
0.492 |
|
| 2022 |
Whittall-Garcia L, Gladman DD, Urowitz MB, Su J, Touma Z, Johnson SR. The new EULAR/ACR 2019 SLE classification criteria: A predictor of long-term outcomes. Seminars in Arthritis and Rheumatism. 57: 152103. PMID 36219896 DOI: 10.1016/j.semarthrit.2022.152103 |
0.443 |
|
| 2022 |
Alforaih N, Whittall-Garcia L, Touma Z. A Review of Lupus Nephritis. The Journal of Applied Laboratory Medicine. PMID 35932197 DOI: 10.1093/jalm/jfac036 |
0.325 |
|
| 2022 |
Whittall-Garcia L, Goliad K, Kim M, Bonilla D, Gladman D, Urowitz M, Fortin PR, Atenafu EG, Touma Z, Wither J. Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis. Frontiers in Immunology. 13: 889931. PMID 35711439 DOI: 10.3389/fimmu.2022.889931 |
0.451 |
|
| 2021 |
Johnson SR, Gladman DD, Brunner HI, Isenberg D, Clarke AE, Barber MRW, Arnaud L, Fortin PR, Mosca M, Voskuyl A, Manzi S, Aranow C, Askanase A, Alarcón GS, Bae SC, ... ... Touma Z, et al. Evaluating the construct of damage in systemic lupus erythematosus. Arthritis Care & Research. PMID 34962100 DOI: 10.1002/acr.24849 |
0.501 |
|
| 2021 |
Whittall-Garcia L, Gladman DD, Urowitz M, Su J, Touma Z, Johnson SR. Response to: Correspondence on "New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE" by Whittall Garcia . Annals of the Rheumatic Diseases. PMID 34344704 DOI: 10.1136/annrheumdis-2021-221014 |
0.454 |
|
| 2021 |
Sivakumaran J, Harvey P, Omar A, Tayer-Shifman O, Urowitz MB, Gladman DD, Anderson N, Su J, Touma Z. Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus. Lupus Science & Medicine. 8. PMID 34045359 DOI: 10.1136/lupus-2020-000448 |
0.458 |
|
| 2021 |
Aringer M, Brinks R, Dörner T, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, ... ... Touma Z, et al. European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Annals of the Rheumatic Diseases. PMID 33568386 DOI: 10.1136/annrheumdis-2020-219373 |
0.465 |
|
| 2021 |
Whittall Garcia LP, Gladman DD, Urowitz M, Touma Z, Su J, Johnson SR. New EULAR/ACR 2019 SLE Classification Criteria: defining ominosity in SLE. Annals of the Rheumatic Diseases. PMID 33452003 DOI: 10.1136/annrheumdis-2020-218670 |
0.531 |
|
| 2021 |
Mai L, Asaduzzaman A, Noamani B, Fortin PR, Gladman DD, Touma Z, Urowitz MB, Wither J. The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. Arthritis Research & Therapy. 23: 29. PMID 33451338 DOI: 10.1186/s13075-021-02414-0 |
0.52 |
|
| 2021 |
Moazzami M, Strand V, Su J, Touma Z. Dual trajectories of fatigue and disease activity in an inception cohort of adults with systemic lupus erythematosus over 10 years. Lupus. 961203320983892. PMID 33413006 DOI: 10.1177/0961203320983892 |
0.312 |
|
| 2020 |
Johnson SR, Brinks R, Costenbader KH, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, ... ... Touma Z, et al. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Annals of the Rheumatic Diseases. PMID 32816709 DOI: 10.1136/Annrheumdis-2020-217162 |
0.59 |
|
| 2020 |
Strand V, Simon LS, Meara AS, Touma Z. Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review. Lupus Science & Medicine. 7. PMID 32591423 DOI: 10.1136/Lupus-2019-000373 |
0.347 |
|
| 2020 |
Touma Z, Gladman DD, Zandy M, Su J, Anderson N, Urowitz MB. Identifying a response for the systemic lupus erythematosus disease activity glucocorticoid index (SLEDAI-2KG). Arthritis Care & Research. PMID 32433815 DOI: 10.1002/Acr.24261 |
0.585 |
|
| 2020 |
Eldeiry D, Zandy M, Tayer-Shifman OE, Kwan A, Marzouk S, Su J, Bingham K, Touma Z. Association between depression and anxiety with skin and musculoskeletal clinical phenotypes in systemic lupus erythematosus. Rheumatology (Oxford, England). PMID 32221602 DOI: 10.1093/Rheumatology/Keaa098 |
0.334 |
|
| 2020 |
Fung W, Lim LSH, Tomlinson G, Engel L, Su J, Diaz-Martinez JP, Touma Z. Joint trajectories of disease activity, and physical and mental health-related quality of life in an inception lupus cohort. Rheumatology (Oxford, England). PMID 32191334 DOI: 10.1093/Rheumatology/Keaa091 |
0.301 |
|
| 2020 |
Aringer M, Brinks R, Costenbader K, Boumpas D, Daikh D, Jayne D, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Diamond B, Jacobsen S, McCune WJ, Ruiz-Irastorza G, ... ... Touma Z, et al. O8 Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease Lupus Science & Medicine. 7. DOI: 10.1136/Lupus-2020-Eurolupus.21 |
0.561 |
|
| 2020 |
Touma Z, Hoskin B, Atkinson C, Bell D, Pike J, Lofland JH, Berry P, Karyekar C, Costenbader K. Ab1170 The Impact Of High Disease Activity As Measured By Sledai And Drug Burden-On Healthcare Utilization, Quality Of Life And Work Productivity In Systemic Lupus Erythematosus Patients Annals of the Rheumatic Diseases. 79: 1871-1872. DOI: 10.1136/Annrheumdis-2020-Eular.5872 |
0.454 |
|
| 2020 |
Touma Z, Hoskin B, Atkinson C, Bell D, Massey O, Lofland JH, Berry P, Karyekar C, Costenbader K. Thu0246 Diagnostic Cluster Profiling Of Patients In A Real-World Data Set With Systemic Lupus Erythematosus Annals of the Rheumatic Diseases. 79: 350-350. DOI: 10.1136/Annrheumdis-2020-Eular.5865 |
0.314 |
|
| 2020 |
Johnson S, Brinks R, Costenbader K, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas D, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, ... ... Touma Z, et al. Thu0271 Performance Of The Eular/Acr 2019 Classification Criteria For Systemic Lupus Erythematosus In Early Disease, Across Sexes And Ethnicities Annals of the Rheumatic Diseases. 79: 362-362. DOI: 10.1136/Annrheumdis-2020-Eular.2324 |
0.511 |
|
| 2019 |
Tayer-Shifman OE, Green R, Beaton D, Ruttan L, Wither JE, Tartaglia MC, Kakvan M, Lombardi S, Anderson N, Su J, Bonilla D, Zandy M, Choi MY, Fritzler MJ, Touma Z. Validity evidence supports the use of automated neuropsychological assessment metrics as a screening tool for cognitive impairment in lupus. Arthritis Care & Research. PMID 31628718 DOI: 10.1002/Acr.24096 |
0.313 |
|
| 2019 |
Touma Z, Cervera R, Brinks R, Lorenzoni V, Tani C, Hoyer BF, Costenbader KH, Sebastian GD, Navarra SV, Bonfa E, Ramsey-Goldman R, Tedeschi SK, Dörner T, Johnson SR, Aringer M, et al. Associations among classification criteria items within systemic lupus erythematosus. Arthritis Care & Research. PMID 31560454 DOI: 10.1002/Acr.24078 |
0.375 |
|
| 2019 |
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, ... ... Touma Z, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis & Rheumatology (Hoboken, N.J.). PMID 31385462 DOI: 10.1002/Art.40930 |
0.553 |
|
| 2019 |
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, ... ... Touma Z, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases. PMID 31383717 DOI: 10.1136/Annrheumdis-2018-214819 |
0.553 |
|
| 2019 |
Webber D, Cao J, Dominguez D, Gladman DD, Levy DM, Ng L, Paterson AD, Touma Z, Urowitz MB, Wither JE, Silverman ED, Hiraki LT. Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE. Rheumatology (Oxford, England). PMID 31236574 DOI: 10.1093/Rheumatology/Kez220 |
0.535 |
|
| 2019 |
Tayer-Shifman OE, Touma Z. Drs. Tayer-Shifman and Touma reply. The Journal of Rheumatology. 46: 653. PMID 31154447 DOI: 10.3899/Jrheum.181290 |
0.351 |
|
| 2019 |
Bangert E, Wakani L, Merchant M, Strand V, Touma Z. Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies. Patient Related Outcome Measures. 10: 1-7. PMID 30666173 DOI: 10.2147/Prom.S134326 |
0.409 |
|
| 2019 |
Webber D, Cao J, Dominguez D, Gladman DD, Levy D, Ng L, Paterson A, Touma Z, Urowitz MB, Wither J, Silverman ED, Hiraki LT. 60 Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset with SLE Lupus Science & Medicine. 6. DOI: 10.1136/Lupus-2019-Lsm.60 |
0.536 |
|
| 2019 |
Sivakumaran J, Harvey P, Omar A, Urowitz MB, Gladman DD, Anderson N, Su J, Touma Z. 291 Assessment of the QRISK2, QRISK3, SLE cardiovascular risk equation, modified framingham and framingham risk calculators as predictors of cardiovascular disease events in systemic lupus erythematosus Lupus Science & Medicine. 6. DOI: 10.1136/Lupus-2019-Lsm.291 |
0.542 |
|
| 2019 |
Touma Z, Gladman DD, Fei K, Gregan YI, Gordon R, Lo KH, Rose S, Urowitz MB. 10 Performance of SLEDAI-2K Responder Index-50 in a Randomized Placebo-Controlled Trial with Ustekinumab (UST) in Systemic Lupus Erythematosus Lupus Science & Medicine. 6. DOI: 10.1136/Lupus-2019-Lsm.10 |
0.613 |
|
| 2019 |
Collins C, Cortés-Hernández J, García M, Kempis Jv, Schwarting A, Touma Z, Ferrante S, Kurtinecz M, Gairy K. Fri0189 Pooled Analysis Of The Real-World Effectiveness Of Belimumab In Treatment Of Systemic Lupus Erythematosus Using Multi-Country Data From The Observe Studies Annals of the Rheumatic Diseases. 78: 771-772. DOI: 10.1136/Annrheumdis-2019-Eular.7637 |
0.448 |
|
| 2019 |
Eldeiry D, Zandy M, Tayer-Shifman O, Marzouk S, Su J, Touma Z. Fri0669 Depression And Anxiety And Their Clinical Correlates In Systemic Lupus Erythematosus (Sle) Annals of the Rheumatic Diseases. DOI: 10.1136/Annrheumdis-2019-Eular.7595 |
0.338 |
|
| 2019 |
Touma Z, Hoskin B, Atkinson C, Bell D, Massey O, Lofland JH, Berry P, Karyekar C, Costenbader K. Ab0486 Lack Of Consistent Standard Of Care In Systemic Lupus Erythematosus Patients In Real World Annals of the Rheumatic Diseases. 78: 1706-1706. DOI: 10.1136/Annrheumdis-2019-Eular.4392 |
0.403 |
|
| 2019 |
Touma Z, Hoskin B, Atkinson C, Bell D, Massey O, Lofland JH, Berry P, Karyekar C, Costenbader K. Fri0178 Cluster Profiling Of Patients In A Real-World Data Set With Systemic Lupus Erythematosus And Their Associated Treatments Annals of the Rheumatic Diseases. 78: 763-763. DOI: 10.1136/Annrheumdis-2019-Eular.4302 |
0.32 |
|
| 2019 |
Costenbader K, Hoskin B, Atkinson C, Bell D, Massey O, Lofland JH, Berry P, Karyekar C, Touma Z. Fri0256 Assessing The Prevalence And Use Of Validated Systemic Lupus Erythematosus Disease Activity Metrics In Real World Practice Annals of the Rheumatic Diseases. 78: 807-808. DOI: 10.1136/Annrheumdis-2019-Eular.4239 |
0.451 |
|
| 2019 |
Touma Z, Gladman DD, Rose S, Fei K, Gregan YI, Gordon R, Lo KH, Urowitz MB. Thu0250 Early Improvement In Sledai-2K Responder Index-50 Predicts Sri-4 Response In A Randomized Placebo-Controlled Trial Of Ustekinumab (Ust) In Systemic Lupus Erythematosus Annals of the Rheumatic Diseases. 78: 402-403. DOI: 10.1136/Annrheumdis-2019-Eular.230 |
0.574 |
|
| 2019 |
Sivakumaran J, Harvey P, Su J, Omar A, Anderson N, Gladman DD, Urowitz MB, Touma Z. Thu0688 Assessment Of The Qrisk2, Qrisk3, Sle Cardiovascular Risk Equation, Framingham And Modified Framingham Risk Calculators As Predictors Of Cardiovascular Disease Events In Systemic Lupus Erythematosus Annals of the Rheumatic Diseases. 78: 641-643. DOI: 10.1136/Annrheumdis-2019-Eular.1146 |
0.535 |
|
| 2018 |
Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB. Disease course patterns in systemic lupus erythematosus. Lupus. 961203318817132. PMID 30526328 DOI: 10.1177/0961203318817132 |
0.57 |
|
| 2018 |
Kwan A, Katz P, Touma Z. The assessment of anxiety and depression and its associated factors in systemic lupus erythematosus. Current Rheumatology Reviews. PMID 30255761 DOI: 10.2174/1573397114666180926101513 |
0.305 |
|
| 2018 |
van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, Chevrier M, Triebel M, Jordan JL, Rose S. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet (London, England). PMID 30249507 DOI: 10.1016/S0140-6736(18)32167-6 |
0.315 |
|
| 2018 |
Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, Barr S, Bergeron L, Bernatsky S, Bourre-Tessier J, Clarke A, Baril-Dionne A, Dutz J, Ensworth S, Fifi-Mah A, Fortin PR, Gladman DD, Haaland D, ... ... Touma Z, et al. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. The Journal of Rheumatology. PMID 30173152 DOI: 10.3899/Jrheum.171459 |
0.569 |
|
| 2018 |
Tayer-Shifman OE, Rosen CF, Wakani L, Touma Z. Novel biological therapeutic approaches to cutaneous lupus erythematosus. Expert Opinion On Biological Therapy. PMID 30118337 DOI: 10.1080/14712598.2018.1513484 |
0.359 |
|
| 2018 |
Keeling SO, Vandermeer B, Medina J, Chatterley T, Nevskaya T, Pope J, Alaburubalnabi Z, Bissonauth A, Touma Z. Measuring Disease Activity and Damage with Validated Metrics: A Systematic Review on Mortality and Damage in Systemic Lupus Erythematosus. The Journal of Rheumatology. PMID 30111638 DOI: 10.3899/Jrheum.171310 |
0.397 |
|
| 2018 |
Elalouf O, Keeling SO, Touma Z. Subcutaneous belimumab in the treatment of systemic lupus erythematosus. Immunotherapy. PMID 30105936 DOI: 10.2217/Imt-2018-0061 |
0.404 |
|
| 2018 |
Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB. Clinical remission and low disease activity have comparable outcomes over 10 years in systemic lupus erythematosus. Arthritis Care & Research. PMID 30055090 DOI: 10.1002/Acr.23720 |
0.577 |
|
| 2018 |
Mosca M, Costenbader KH, Johnson SR, Lorenzoni V, Sebastiani GD, Hoyer BF, Navarra S, Bonfa E, Ramsey-Goldman R, Medina-Rosas J, Piga M, Tani C, Tedeschi SK, Dörner T, Aringer M, ... Touma Z, et al. How Do Patients with Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. Arthritis & Rheumatology (Hoboken, N.J.). PMID 30035365 DOI: 10.1002/Art.40674 |
0.461 |
|
| 2018 |
Alharbi S, Ahmad Z, Bookman AA, Touma Z, Sanchez-Guerrero J, Mitsakakis N, Johnson SR. Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome. The Journal of Rheumatology. PMID 30008448 DOI: 10.3899/Jrheum.170953 |
0.401 |
|
| 2018 |
Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB. Monophasic Disease Course in Systemic Lupus Erythematosus. The Journal of Rheumatology. PMID 29858240 DOI: 10.3899/Jrheum.171319 |
0.61 |
|
| 2018 |
Shinde R, Hezaveh K, Halaby MJ, Kloetgen A, Chakravarthy A, da Silva Medina T, Deol R, Manion KP, Baglaenko Y, Eldh M, Lamorte S, Wallace D, Chodisetti SB, Ravishankar B, Liu H, ... ... Touma Z, et al. Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans. Nature Immunology. PMID 29760532 DOI: 10.1038/S41590-018-0107-1 |
0.36 |
|
| 2018 |
Wither JE, Prokopec SD, Noamani B, Chang NH, Bonilla D, Touma Z, Avila-Casado C, Reich HN, Scholey J, Fortin PR, Boutros PC, Landolt-Marticorena C. Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: Clinical/pathologic associations and etiologic mechanisms. Plos One. 13: e0196117. PMID 29742110 DOI: 10.1371/Journal.Pone.0196117 |
0.396 |
|
| 2018 |
Touma Z, Gladman DD, Su J, Anderson N, Urowitz MB. A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index. Rheumatology (Oxford, England). PMID 29688532 DOI: 10.1093/Rheumatology/Key103 |
0.513 |
|
| 2018 |
Wither J, Chang N, Johnson SR, Hafiz W, Manion K, Ferri D, Karanxha A, Noamani B, Bonilla D, Rusta-Sellehy S, Lisnevskaia L, Touma Z, Silverman E, Bookman A, Landolt-Marticorena C, et al. AI-09 T follicular helper (Tfh) cells are increased in asymptomatic anti-nuclear antibody (ANA)+ individuals and appear to play a role in epitope spreading Lupus Science & Medicine. 5. DOI: 10.1136/Lupus-2018-Lsm.9 |
0.357 |
|
| 2018 |
Touma Z, Green R, Engel L, Tartaglia C, Ruttan L, Lombardi S, Anderson N, Su J, Colosimo K, Vitti M, Bonilla D, Wither J, Fritzler M, Beaton D. CS-37 Prevalence of cognitive impairment in systemic lupus erythematosus assessed by a comprehensive neuropsychological battery Lupus Science & Medicine. 5. DOI: 10.1136/Lupus-2018-Lsm.72 |
0.326 |
|
| 2018 |
Keeling S, Alabdurubalnabi Z, Avina-Zubieta A, Barr S, Bergeron L, Bernatsky S, Bourre-Tessier J, Clarke A, Baril-Dionne A, Dutz J, Ensworth S, Fifi-Mah A, Fortin PR, Gladman D, Haaland D, ... ... Touma Z, et al. CS-36 Recommendations for the assessment of systemic lupus erythematosus in canada Lupus Science & Medicine. 5. DOI: 10.1136/Lupus-2018-Lsm.71 |
0.575 |
|
| 2018 |
Engel L, Su J, Nalder E, Goverover Y, Gignac M, Tartaglia C, Anderson N, Touma Z. CS-22 Confirmatory factor analysis of the patient-reported perceived deficits questionnaire in systemic lupus erythematous: cautions for use of subscales Lupus Science & Medicine. 5. DOI: 10.1136/Lupus-2018-Lsm.57 |
0.378 |
|
| 2018 |
Urowitz M, Gladman D, Su J, Anderson N, Touma Z. S1D:5 Sle disease activity index glucocorticosteroid index (sledai-2kg) identifies more responders than sledai-2k Lupus Science & Medicine. 5. DOI: 10.1136/Lupus-2018-Abstract.5 |
0.416 |
|
| 2018 |
Tselios K, Gladman D, Touma Z, Su J, Anderson N, Urowitz M. SAT0451 Disease course patterns in systemic lupus erythematosus Annals of the Rheumatic Diseases. 77: 1085-1085. DOI: 10.1136/Annrheumdis-2018-Eular.5680 |
0.448 |
|
| 2018 |
Touma Z, Beaton D, Tartaglia C, Ruttan L, Lombardi S, Su J, Wither J, Fritzler M, Green R. SAT0418 Can the automated neuropsychological assessment metrics (ANAM) predict cognitive impairment compared to a comprehensive neuropsychological battery in patients with systemic lupus erythematosus (SLE) Annals of the Rheumatic Diseases. DOI: 10.1136/Annrheumdis-2018-Eular.5573 |
0.375 |
|
| 2018 |
Touma Z, Gladman D, Su J, Anderson NM, Urowitz MB. FRI0395 Sle disease activity index glucocorticoid index (SLEDAI-2KG) identifies more responders than sledai-2k Annals of the Rheumatic Diseases. 77: 730-731. DOI: 10.1136/Annrheumdis-2018-Eular.5519 |
0.567 |
|
| 2018 |
Richard N, Haroon N, Tomlinson GA, Sari I, Touma Z, Inman RD. FRI0208 Ankylosing spondylitis quality of life: defining minimal clinically important change Annals of the Rheumatic Diseases. 77: 645-645. DOI: 10.1136/Annrheumdis-2018-Eular.5020 |
0.337 |
|
| 2018 |
Touma Z, Urowitz MB, Gladman DD, Wagner C, Hsu B, Chevrier M, Rose S, Zhou B, Gordon R. FRI0339 Sledai-2k responder index-50 is effective in demonstrating partial response in a phase 2, randomised placebo-controlled study of ustekinumab in patients with active systemic lupus erythematosus Annals of the Rheumatic Diseases. 77: 705-706. DOI: 10.1136/Annrheumdis-2018-Eular.4877 |
0.395 |
|
| 2018 |
Aringer M, Costenbader KH, Brinks R, Boumpas D, Daikh D, Jayne D, Kamen D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Diamond B, Jacobsen S, McCune WJ, Ruiz-Irastorza G, ... ... Touma Z, et al. OP0020 Validation of new systemic lupus erythematosus classification criteria Annals of the Rheumatic Diseases. 77: 60-60. DOI: 10.1136/Annrheumdis-2018-Eular.3679 |
0.561 |
|
| 2018 |
Alharbi S, Ahmad Z, Bookman A, Touma Z, Sanchez-Guerrero J, Mitsakakis N, Johnson SR. THU0423 Epidemiology and survival of systemic sclerosis-systemic lupus erythematosus overlap syndrome Annals of the Rheumatic Diseases. 77: 425-425. DOI: 10.1136/Annrheumdis-2018-Eular.1576 |
0.439 |
|
| 2018 |
Kwan A, Marzouk S, Ghanean H, Ali K, Anderson N, Su J, Touma Z. THU0344 Assessment of the psychometric properties of patient-reported outcomes of depression in SLE Annals of the Rheumatic Diseases. 77: 390-390. DOI: 10.1136/Annrheumdis-2018-Eular.1094 |
0.306 |
|
| 2017 |
Touma Z, Gladman DD. Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. Lupus Science & Medicine. 4: e000239. PMID 29344386 DOI: 10.1136/Lupus-2017-000239 |
0.391 |
|
| 2017 |
Fung WA, Su J, Touma Z. Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis: Results from a Single Lupus Cohort. Biomed Research International. 2017: 5312960. PMID 28904963 DOI: 10.1155/2017/5312960 |
0.308 |
|
| 2017 |
Nantes SG, Su J, Dhaliwal A, Colosimo K, Touma Z. Performance of Screening Tests for Cognitive Impairment in Systemic Lupus Erythematosus. The Journal of Rheumatology. PMID 28864643 DOI: 10.3899/Jrheum.161125 |
0.318 |
|
| 2017 |
Nantes SG, Strand V, Su J, Touma Z. Comparison of the sensitivity to change of the 36-item short form health survey and the lupusqol using various definitions of minimal clinically important differences in patients with active systemic lupus erythematosus. Arthritis Care & Research. PMID 28320078 DOI: 10.1002/Acr.23240 |
0.433 |
|
| 2017 |
Touma Z, Sayani A, Pineau CA, Fortin I, Matsos M, Ecker GA, Chow A, Iczkovitz S. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study. Rheumatology International. PMID 28280970 DOI: 10.1007/S00296-017-3682-9 |
0.461 |
|
| 2017 |
Al Rayes H, Harvey PJ, Gladman DD, Su J, Sabapathy A, Urowitz MB, Touma Z. Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease. Arthritis Research & Therapy. 19: 31. PMID 28183339 DOI: 10.1186/S13075-017-1240-1 |
0.578 |
|
| 2017 |
Fung W, Su J, Touma Z, Gladman D. 445 Predictors of good long-term renal outcomes Lupus Science & Medicine. 4. DOI: 10.1136/Lupus-2017-000215.445 |
0.303 |
|
| 2017 |
Medina-Rosas J, Gladman D, Su J, Urowitz M, Touma Z. 219 Effect of complete or partial proteinuria recovery compared to no recovery at 2 years after the diagnosis of lupus nephritis on long term outcomes Lupus Science & Medicine. 4. DOI: 10.1136/Lupus-2017-000215.219 |
0.474 |
|
| 2017 |
Touma Z, Gladman D, Su J, Urowitz M. 11 Development and initial validation of a novel lupus disease activity index to account for glucocorticoids: SLEDAI-2K glucocorticoids index (SGI) Lupus Science & Medicine. 4. DOI: 10.1136/Lupus-2017-000215.11 |
0.392 |
|
| 2016 |
Yap KS, Urowitz MB, Mahood Q, Medina-Rosas J, Sabapathy A, Lawson D, Su J, Gladman DD, Touma Z. The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort. Seminars in Arthritis and Rheumatism. PMID 27769590 DOI: 10.1016/J.Semarthrit.2016.09.008 |
0.508 |
|
| 2016 |
Cramarossa G, Urowitz MB, Su J, Gladman D, Touma Z. Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus. Lupus. PMID 27522094 DOI: 10.1177/0961203316664597 |
0.524 |
|
| 2016 |
Medina-Rosas J, Al-Rayes H, Moustafa AT, Touma Z. Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials. Expert Opinion On Biological Therapy. PMID 27429254 DOI: 10.1080/14712598.2016.1214263 |
0.334 |
|
| 2016 |
Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, Ruiz-Irastorza G, Hughes G. Systemic lupus erythematosus. Nature Reviews. Disease Primers. 2: 16039. PMID 27306639 DOI: 10.1097/00005792-199303000-00005 |
0.516 |
|
| 2016 |
Polachek A, Touma Z, Anderson M, Eder L. Risk of cardiovascular morbidity in patients with psoriatic arthritis: A meta-analysis of observational studies. Arthritis Care & Research. PMID 27111228 DOI: 10.1002/Acr.22926 |
0.344 |
|
| 2016 |
Touma Z, Thavaneswaran A, Chandran V, Pellett F, Cook RJ, Gladman DD. Clinical and Demographic Characteristics of Erosion-free and Erosion-present Status in Psoriatic Arthritis in a Cohort Study. The Journal of Rheumatology. PMID 27036389 DOI: 10.3899/Jrheum.150466 |
0.399 |
|
| 2016 |
Fidler L, Keen KJ, Touma Z, Mittoo S. Impact of pulmonary disease on patient-reported outcomes and patient-performed functional testing in systemic lupus erythematosus Lupus. 25: 1004-1011. DOI: 10.1177/0961203316630818 |
0.376 |
|
| 2016 |
Touma Z, Gladman DD, Su J, Urowitz MB. CE-18 Time to recovery of individual lupus manifestations on standard of care treatment Lupus Science & Medicine. 3. DOI: 10.1136/Lupus-2016-000179.97 |
0.587 |
|
| 2016 |
Keeling SO, Medina J, Nevskaya T, Pope J, Alabdurubalnabi Z, Bissonauth A, Touma Z. CE-36 Clinical measures and indices of disease activity and damage as predictors of morbidity and mortality in systemic lupus erythematosus (SLE): a systematic review of the literature Lupus Science & Medicine. 3. DOI: 10.1136/Lupus-2016-000179.115 |
0.454 |
|
| 2016 |
Wither J, Prokopec S, Noamani B, Bonilla D, Touma Z, Avila-Casado C, Reich H, Scholey J, Boutros P, Fortin P, Landolt-Marticorena C. FRI0307 Changes in Urinary Biomarker Levels Can Predict Treatment Responses in Lupus Nephritis Annals of the Rheumatic Diseases. 75: 546.2-546. DOI: 10.1136/Annrheumdis-2016-Eular.5818 |
0.35 |
|
| 2016 |
Touma Z, Costenbader KH, Johnson S, Mosca M, Hoyer BF, Navara S, Bonfa E, Ramsey-Goldman R, Medina-Rosas J, Tani C, Fine A, Tedeschi S, Lorenzoni V, Sebastiani GD, Dorner T, et al. FRI0341 Do Patients with SLE at Onset Differ from Mimickers? A Comparison of Clinical and Serological Manifestations in A Multicenter Cohort To Inform The Development of New Classification Criteria for SLE Annals of the Rheumatic Diseases. 75: 558-558. DOI: 10.1136/Annrheumdis-2016-Eular.4437 |
0.432 |
|
| 2016 |
Touma Z, Urowitz MB. Systemic Glucocorticoids Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects. 521-531. DOI: 10.1016/B978-0-12-801917-7.00061-9 |
0.492 |
|
| 2015 |
Medina-Rosas J, Yap KS, Anderson M, Su J, Touma Z. Utility of Urinary Protein Creatinine Ratio and Protein Content in a 24 Hour-Urine Collection in Lupus: Systematic Review and Meta-Analysis. Arthritis Care & Research. PMID 26714024 DOI: 10.1002/Acr.22828 |
0.338 |
|
| 2015 |
Medina-Rosas J, Gladman DD, Su J, Sabapathy A, Urowitz MB, Touma Z. Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus. Arthritis Research & Therapy. 17: 296. PMID 26497948 DOI: 10.1186/S13075-015-0808-X |
0.455 |
|
| 2015 |
Touma Z, Gladman DD, Su J, Ibañez D, Urowitz MB. SLEDAI-2K Does Not Conceal Worsening in a Particular System When There Is Overall Improvement. The Journal of Rheumatology. 42: 1401-5. PMID 26077403 DOI: 10.3899/Jrheum.141088 |
0.604 |
|
| 2015 |
Nantes S, Urowitz M, Gladman D, Su J, Dhaliwal A, Touma Z. SAT0386 What is the Best Screening Test to Identify Lupus Patients with Cognitive Impairment in an Ambulatory Setting? Annals of the Rheumatic Diseases. 74: 799.1-799. DOI: 10.1136/Annrheumdis-2015-Eular.5021 |
0.373 |
|
| 2015 |
Wither J, Prokopec S, Noamani B, Bonilla D, Touma Z, Reich H, Scholey J, Fortin P, Boutros P, Landolt-Marticorena C. OP0091 A Low Density Granulocyte Gene Expression Signature Distinguishes Between Active Patients with and Without Nephritis in Systemic Lupus Erythematosus (SLE) Annals of the Rheumatic Diseases. 74: 103.1-103. DOI: 10.1136/Annrheumdis-2015-Eular.4965 |
0.388 |
|
| 2015 |
Medina J, Gladman D, Urowitz M, Su J, Sabapaty A, Touma Z. SAT0404 Spot Urine Protein/Creatinine Ratio is Useful in Screening for Proteinuria but Should Not Substitute 24 hours Urine Collection Sample to Quantify Proteinuria in Lupus Annals of the Rheumatic Diseases. 74: 805.2-806. DOI: 10.1136/Annrheumdis-2015-Eular.4852 |
0.475 |
|
| 2014 |
Al Rayes H, Touma Z. Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus. Drug Design, Development and Therapy. 8: 2303-10. PMID 25429203 DOI: 10.2147/Dddt.S49778 |
0.349 |
|
| 2014 |
Touma Z, Urowitz MB, Ibañez D, Gladman DD. Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. The Journal of Rheumatology. 41: 688-97. PMID 24429170 DOI: 10.3899/Jrheum.130005 |
0.537 |
|
| 2014 |
Touma Z, Gladman D, Ibanez D, Urowitz M. OP0042 Do We Know How and When to Stop Immunosuppressants in Lupus Patients? Annals of the Rheumatic Diseases. 73: 76-76. DOI: 10.1136/Annrheumdis-2014-Eular.5739 |
0.55 |
|
| 2013 |
Arayssi T, Touma Z, Nikpour M, Ghandour L. The assessment of disease activity in rheumatic diseases. International Journal of Rheumatology. 2013: 275691. PMID 24307902 DOI: 10.1155/2013/275691 |
0.618 |
|
| 2013 |
Dua AB, Touma Z, Toloza S, Jolly M. Top 10 recent developments in health-related quality of life in patients with systemic lupus erythematosus. Current Rheumatology Reports. 15: 380. PMID 24178589 DOI: 10.1007/S11926-013-0380-9 |
0.413 |
|
| 2013 |
Alnaqbi KA, Touma Z, Passalent L, Johnson SR, Tomlinson GA, Carty A, Inman RD. Development, sensibility, and reliability of the Toronto Axial Spondyloarthritis Questionnaire in inflammatory bowel disease. The Journal of Rheumatology. 40: 1726-35. PMID 23996291 DOI: 10.3899/Jrheum.130048 |
0.364 |
|
| 2013 |
Touma Z, Urowitz MB, Gladman DD. Systemic lupus erythematosus disease activity index 2000 responder index-50 website. The Journal of Rheumatology. 40: 733. PMID 23637378 DOI: 10.3899/Jrheum.130030 |
0.552 |
|
| 2013 |
Touma Z, Gladman DD, Urowitz MB. Vaccination and auto-immune rheumatic diseases: lessons learnt from the 2009 H1N1 influenza virus vaccination campaign. Current Opinion in Rheumatology. 25: 164-70. PMID 23370371 DOI: 10.1097/Bor.0B013E32835D2B7B |
0.449 |
|
| 2013 |
Touma Z, Urowitz MB, Gladman DD. Systemic lupus erythematosus: an update on current pharmacotherapy and future directions. Expert Opinion On Biological Therapy. 13: 723-37. PMID 23339281 DOI: 10.1517/14712598.2013.764411 |
0.532 |
|
| 2013 |
Touma Z, Haddad A, Gladman DD, Uleryk EM, Urowitz MB. Skin nontuberculous mycobacterial infection in systemic lupus erythematosus: an unusual skin infection mimicking lupus vasculitis. Seminars in Arthritis and Rheumatism. 42: 498-506. PMID 23332736 DOI: 10.1016/J.Semarthrit.2012.08.002 |
0.497 |
|
| 2013 |
Touma Z, Gladman DD, MacKinnon A, Carette S, Abu-Shakra M, Askanase A, Nived O, Hanly JG, Landolt-Marticorena C, Tam LS, Toloza S, Nikpour M, Riddell C, Steiman A, Eder L, et al. Development and assessment of users' satisfaction with the systemic lupus erythematosus disease activity index 2000 responder index-50 website. The Journal of Rheumatology. 40: 34-9. PMID 23118108 DOI: 10.3899/Jrheum.120754 |
0.624 |
|
| 2013 |
Touma Z, Urowitz MB, Ibanez D, Taghavi-Zadeh S, Gladman DD. AB0383 Measuring partial and complete recovery in active organ systems of lupus patients on standard of care treatment Annals of the Rheumatic Diseases. 72: A904.2-A904. DOI: 10.1136/Annrheumdis-2013-Eular.2705 |
0.568 |
|
| 2013 |
Touma Z, Thavaneswaran A, Chandran V, Gladman DD. SAT0308 Responsiveness of Patient Reported Outcomes to Biological Treatment in Psoriatic Arthritis Annals of the Rheumatic Diseases. 72: A688.1-A688. DOI: 10.1136/Annrheumdis-2013-Eular.2033 |
0.352 |
|
| 2013 |
Touma Z, Urowitz M, Ibañez D, Gladman D. THU0197 Time to recovery from proteinuria in lupus nephritis patients receiving standard of care treatment Annals of the Rheumatic Diseases. 71: 222.1-222. DOI: 10.1136/Annrheumdis-2012-Eular.2162 |
0.523 |
|
| 2013 |
Touma Z, Urowitz MB, Gladman DD. Outcome measures in systemic lupus erythematosus Indian Journal of Rheumatology. 8. DOI: 10.1016/J.Injr.2013.11.015 |
0.583 |
|
| 2012 |
Touma Z, Gladman DD, Ibañez D, Urowitz MB. SLEDAI-2K Responder Index 50 captures 50% improvement in disease activity over 10 years. Lupus. 21: 1305-11. PMID 22800940 DOI: 10.1177/0961203312454344 |
0.565 |
|
| 2012 |
Touma Z, Urowitz MB, Taghavi-Zadeh S, Ibañez D, Gladman DD. Systemic lupus erythematosus disease activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months. Rheumatology (Oxford, England). 51: 1814-9. PMID 22718868 DOI: 10.1093/Rheumatology/Kes146 |
0.585 |
|
| 2012 |
Touma Z, Thavaneswaran A, Chandran V, Gladman DD. Does the change in season affect disease activity in patients with psoriatic arthritis? Annals of the Rheumatic Diseases. 71: 1370-3. PMID 22504562 DOI: 10.1136/Annrheumdis-2011-201208 |
0.421 |
|
| 2012 |
Touma Z, Gladman DD, Ibañez D, Urowitz MB. Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients. Rheumatology (Oxford, England). 51: 528-34. PMID 22120460 DOI: 10.1093/Rheumatology/Ker339 |
0.518 |
|
| 2012 |
Touma Z, Gladman D, Urowitz M. Development validation and reliability of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Arthritis Research & Therapy. 14. DOI: 10.1186/Ar3989 |
0.588 |
|
| 2012 |
Touma Z, Gladman DD, Urowitz MB. Clinical Measures, Metrics, and Indices Dubois' Lupus Erythematosus and Related Syndromes: Eighth Edition. 563-581. DOI: 10.1016/B978-1-4377-1893-5.00046-7 |
0.389 |
|
| 2011 |
Touma Z, Eder L, Zisman D, Feld J, Chandran V, Rosen CF, Shen H, Cook RJ, Gladman DD. Seasonal variation in vitamin D levels in psoriatic arthritis patients from different latitudes and its association with clinical outcomes. Arthritis Care & Research. 63: 1440-7. PMID 22121512 DOI: 10.1002/Acr.20530 |
0.313 |
|
| 2011 |
Touma Z, Gladman DD, Ibañez D, Taghavi-Zadeh S, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials. The Journal of Rheumatology. 38: 2395-9. PMID 21885488 DOI: 10.3899/Jrheum.110550 |
0.598 |
|
| 2011 |
Touma Z, Gladman DD, Ibañez D, Urowitz MB. Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus? The Journal of Rheumatology. 38: 1898-905. PMID 21724700 DOI: 10.3899/Jrheum.110007 |
0.573 |
|
| 2011 |
Touma Z, Ghandour L, Sibai A, Puzantian H, Hamdan A, Hamdan O, Menassa J, Uthman I, Arayssi T. Cross-cultural adaptation and validation of Behçet's disease quality of life questionnaire. Bmc Medical Research Methodology. 11: 52. PMID 21507231 DOI: 10.1186/1471-2288-11-52 |
0.309 |
|
| 2011 |
Touma Z, Urowitz MB, Fortin PR, Landolt C, Toloza SM, Riddell C, Chandran V, Eder L, Ghanem A, Ziouzina O, Taghavi-Zadeh S, Ibañez D, Gladman DD. Systemic lupus erythematosus disease activity index 2000 responder index-50: a reliable index for measuring improvement in disease activity. The Journal of Rheumatology. 38: 868-73. PMID 21324961 DOI: 10.3899/Jrheum.101080 |
0.609 |
|
| 2011 |
Touma Z, Urowitz MB, Ibañez D, Gladman DD. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus. 20: 67-70. PMID 21233149 DOI: 10.1177/0961203310385163 |
0.511 |
|
| 2011 |
Touma Z, Gladman DD, Ibañez D, Urowitz MB. Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. The Journal of Rheumatology. 38: 275-84. PMID 21123323 DOI: 10.3899/Jrheum.100724 |
0.603 |
|
| 2011 |
Ibañez D, Gladman DD, Touma Z, Nikpour M, Urowitz MB. Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time. The Journal of Rheumatology. 38: 60-3. PMID 21078718 DOI: 10.3899/Jrheum.100575 |
0.676 |
|
| 2011 |
Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS. Mycophenolate mofetil for induction treatment of lupus nephritis: A systematic review and metaanalysis Journal of Rheumatology. 38: 69-78. PMID 20952473 DOI: 10.3899/Jrheum.100130 |
0.493 |
|
| 2010 |
Touma Z, Gladman DD, Tulloch-Reid D, Toloza SM, Ibañez D, Fortin PR, Urowitz MB. Burden of autoantibodies and association with disease activity and damage in systemic lupus erythematosus. Clinical and Experimental Rheumatology. 28: 525-31. PMID 20659409 |
0.514 |
|
| 2010 |
Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window. Lupus. 19: 49-51. PMID 19910390 DOI: 10.1177/0961203309346505 |
0.521 |
|
| 2008 |
Touma Z, Arayssi T, Kibbi L, Masri AF. Successful treatment of cardiac involvement in dermatomyositis with rituximab. Joint, Bone, Spine : Revue Du Rhumatisme. 75: 334-7. PMID 17988919 DOI: 10.1016/J.Jbspin.2007.05.011 |
0.313 |
|
| 2007 |
Touma Z, Atweh SF, Kibbi L, Arayssi T. Longitudinal myelitis in patient with systemic lupus erythematosus, homozygous proth rombin G20210A and heterozygous MTHFR 677T Lupus. 16: 517-520. PMID 17670851 DOI: 10.1177/0961203307077830 |
0.325 |
|
| Show low-probability matches. |